| Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms |
|
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
| Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
|
The Oncologist |
Myelodysplastic Syndromes (MDS) |
| Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
|
The Oncologist |
Myelodysplastic Syndromes (MDS) |
| Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
|
Oncologist |
Myelodysplastic Syndromes (MDS) |
| Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria |
|
Expert Review of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes |
|
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Myelodysplastic Syndromes (MDS) |
| Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
